AACT exhibits low specificity in cancers, and the protein or glycosylation level of AACT is aberrantly expressed in various tumors, and associated with survival and tumor progression, including ovarian cancer [18], colorectal cancer [41], melanoma [42], and endometrial cancer [43], as well as can be used as a biomarker for cancer monitoring. This evidence concerns the gene SERPINA3 and neoplasm.